|
|
Vaccine Detail
|
Large Multivalent Immunogen (LMI) vaccine |
| Vaccine Information |
- Vaccine Name: Large Multivalent Immunogen (LMI) vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007632
- Type: multivalent immunogen
- Status: Research
- Antigen: SK23-CD80+ cell line
- Preparation: In LMI cell-sized (5-mm diameter) latex or silica spheres serve as a support structure for presenting tumor antigens, by using the SK23-CD80+ cell line to prepare an LMI vaccine. This cell line expresses all common melanoma antigens and was genetically modiļ¬ed to express human B7-1 (CD80). (Jha et al., 2012).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: This screening failed to detect evidence of an antibody response to the vaccine in any patients (Jha et al., 2012).
|
| References |
Jha et al., 2012: Jha G, Miller JS, Curtsinger JM, Zhang Y, Mescher MF, Dudek AZ. Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen Vaccine for the Treatment of Stage IV Melanoma. American journal of clinical oncology. 2012; ; . [PubMed: 23241505].
|
|
